AI Article Synopsis
Article Abstract
Cytomegalovirus (CMV) viremia continues to cause significant morbidity and mortality in kidney transplant patients with clinical complications including organ rejection and death. Whole blood gene expression dynamics in CMV viremic patients from onset of DNAemia through convalescence has not been well studied to date in humans. To evaluate how CMV infection impacts whole blood leukocyte gene expression over time, we evaluated a matched cohort of 62 kidney transplant recipients with and without CMV DNAemia using blood samples collected at multiple time points during the 12-month period after transplant. While transcriptomic differences were minimal at baseline between DNAemic and non-DNAemic patients, hundreds of genes were differentially expressed at the long-term timepoint, including genes enriching for pathways important for macrophages, interferon, and IL-8 signaling. Amongst patients with CMV DNAemia, the greatest amount of transcriptomic change occurred between baseline and 1-week post-DNAemia, with increase in pathways for interferon signaling and cytotoxic T cell function. Time-course gene set analysis of these differentially expressed genes revealed that most of the enriched pathways had a significant time-trend. While many pathways that were significantly down- or upregulated at 1 week returned to baseline-like levels, we noted that several pathways important in adaptive and innate cell function remained upregulated at the long-term timepoint after resolution of CMV DNAemia. Differential expression analysis and time-course gene set analysis revealed the dynamics of genes and pathways involved in the immune response to CMV DNAemia in kidney transplant patients. Understanding transcriptional changes caused by CMV DNAemia may identify the mechanism behind patient vulnerability to CMV reactivation and increased risk of rejection in transplant recipients and suggest protective strategies to counter the negative immunologic impact of CMV. These findings provide a framework to identify immune correlates for risk assessment and guiding need for extending antiviral prophylaxis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634678 | PMC |
| http://dx.doi.org/10.3389/fimmu.2021.750659 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Active cytomegalovirus infection in mechanically ventilated patients with sepsis.
BMC Infect Dis
December 2024
Department of Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Background: Active cytomegalovirus (CMV) infection is associated with poor prognosis in septic patients with critical illness. Patients of septic category are highly likely to benefit from prophylactic antiviral therapy. Nevertheless, the clinical characteristics for CMV reactivation are lacking among septic patients requiring mechanical ventilation.
View Article and Find Full Text PDFMonitoring and Management of Cytomegalovirus Reactivations After Allogeneic Hematopoietic Stem Cell Transplantation in Children: Experience from a Single Pediatric Center.
Diagnostics (Basel)
November 2024
Hematopoietic Stem Cell Transplant Unit, Department of Hemato-Oncology, IRCCS Istituto G. Gaslini, 16147 Genova, Italy.
Background: CMV reactivation represents a frequent complication after HSCT. The aim of this study was to describe the incidence of CMV reactivation in a pediatric HSCT cohort and analyze the potential impact of recipient/donor-related or transplant-related factors on this complication. Furthermore, we analyzed the management of CMV reactivation in order to purpose criteria for pre-emptive therapy.
View Article and Find Full Text PDFEvaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
Clin Transplant
October 2024
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Introduction: Maribavir was recently approved by the FDA, expanding treatment options for post-solid-organ transplant refractory/resistant CMV. We sought to describe the post-marketing experience with maribavir at a large academic transplant center.
Methods: This was a retrospective observational study of all renal transplant recipients treated with maribavir for refractory/resistant CMV DNAemia/disease.
Virus-specific Th17 Cells Are Induced by Human Cytomegalovirus after Renal Transplantation.
J Immunol
December 2024
Center for Vaccines and Immunity, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus OH.
Article Synopsis
- - The study investigates the connection between CMV infection and Th17 cells in kidney transplant recipients, finding that both factors independently raise the risk of late allograft loss.
- - Researchers observed that CMV-specific Th17 cells were present in blood samples and expanded during CMV reactivation, showing distinct characteristics compared to general Th17 cells.
- - The findings suggest that CMV-induced Th17 cells might play a role in causing inflammation that can lead to damage in transplanted kidneys, highlighting a possible pathway for allograft injury.
Secondary anti-viral prophylaxis in solid organ transplant recipients for the prevention of cytomegalovirus relapse: A systematic review and meta-analysis.
Transpl Infect Dis
December 2024
Department of Medicine, Division of Public Health, Infectious Diseases and Occupational Medicine and the William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA.
Article Synopsis
- Cytomegalovirus (CMV) significantly impacts solid organ transplant recipients (SOTRs), with secondary prophylaxis (SP) potentially beneficial in high-risk cases despite not being widely recommended.
- A review of studies up to September 2023 found that while SP with valganciclovir did not notably reduce CMV relapse, it was linked to decreased mortality rates among recipients.
- The overall evidence from six nonrandomized studies is insufficient to make definitive recommendations on SP, highlighting the importance of personalized risk assessments by clinicians.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!